You searched for "adrenal"
Adrenal incidentalomas: what next?
An incidentaloma refers to an adrenal lesion >1cm discovered incidentally during radiologic examination. Identifying a malignant and / or functioning lesion is critical for management. However, as the majority of lesions are benign, the challenge is the identification of malignant...Assessment of the incidental adrenal lesion
Introduction The adrenal glands are seen on CT or MRI surrounded by fat in the peri-renal space. The right adrenal gland lies medial to the right lobe of the liver, lateral to the right crus of the diaphragm and superior...The adrenals
Case 1 A 45-year-old man undergoes a CT of his abdomen to stage a newly diagnosed bowel malignancy. What does the scan show? What findings on a CT scan suggest an adrenal lesion is benign? If the CT scan is...
Oncological Imaging: Urology
Imaging updates on renal tumours, urothelial tumours, prostate, adrenal and retroperitoneal tumours are all covered in this text. Whilst aspects relating to prostate imaging are probably covered better elsewhere, what remains is a decent account nicely contained within a single...
Urological Cancer Management
This was all in all a pretty good read. It covers a wide range of topics authoritatively and with a degree of confidence that allows for quite a focused discussion on a range of malignancies from adrenal glands to penile...
Incidental findings on modern imaging
Incidentalomas can be defined in a variety of ways: 1) Imaging abnormality in a healthy, asymptomatic patient; 2) Imaging abnormality not related to a patient’s symptoms or the organs in question; 3) Findings discovered by chance which can potentially affect...
Urinary tuberculosis and the busy urologist!
This article is a very good read for any busy urologist. When in medical school, we were taught that tuberculosis (TB) was rare in the UK and other developed countries. We have come full circle; now there are increasing cases...
Abiraterone acetate in men with castration-resistant prostate cancer
With emerging results from the Stampede and Latitude studies, abiraterone has taken the forefront in the management of metastatic prostate cancer while researchers try to identify the ideal timing for administration. It is a potent inhibitor of CYP17 which results...
